5-chlorothiophene-2-carboxylic acid [(S)-2-[2-Methyl-3-(2-oxopyrrolidin-1- yl)benzenesulfonylamino]-3-(4-methylpiperazin-1-yl)-3-oxopropyl]amide (SAR107375), a selective and potent orally active dual thrombin and factor Xa inhibitor

Journal of Medicinal Chemistry

Volumn 56, Issue 23, 2013, Pages 9441-9456

  Meneyrol, Jerome ^a   Follmann, Markus ^b,c   Lassalle, Gilbert ^a   Wehner, Volkmar ^b   Barre, Guillaume ^a   Rousseaux, Tristan ^a   Altenburger, Jean Michel ^a   Petit, Frederic ^a   Bocskei, Zsolt ^a   Schreuder, Herman ^b   Alet, Nathalie ^a   Herault, Jean Pascal ^a   Millet, Laurence ^a   Dol, Frederique ^a   Florian, Peter ^b   Schaeffer, Paul ^a   Sadoun, Freddy ^a   Klieber, Sylvie ^a   Briot, Christophe ^a   Bono, Françoise ^a   Herbert, Jean Marc ^a   more..

^a SANOFI   (France)

^b SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^c BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLOROTHIOPHENE 2 CARBOXYLIC ACID [(S) 2 [2 METHYL 3 (2 OXOPYRROLIDIN 1 YL)BENZENESULFONYLAMINO] 3 (4 METHYLPIPERAZIN 1 YL) 3 OXOPROPYL]AMIDE; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN ETEXILATE; RIVAROXABAN; SAR 107375; SERINE; THROMBIN INHIBITOR; TRYPSIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BLEEDING; DRUG ACTIVITY; DRUG HALF LIFE; DRUG STABILITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MICROSOME; NONHUMAN; PROCESS OPTIMIZATION; RAT; THROMBIN TIME; THROMBOCYTE RICH PLASMA; TIME TO MAXIMUM PLASMA CONCENTRATION; VEIN THROMBOSIS; X RAY CRYSTALLOGRAPHY;

EID: 84890473364     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm4005835     Document Type: Article

References (60)

1. Lassen, M. R.; Laux, V. Emergence of new oral antithrombotics: a critical appraisal of their clinical potential Vasc. Health Risk Manage. 2008, 4 (6) 1373-1386
2. Weitz, J. I. Factor Xa and thrombin as targets for new oral anticoagulants Thromb. Res. 2011, 127 (2) S5-S12
3. Straub, A.; Roehrig, S.; Hillisch, A. Oral, direct thrombin and factor Xa inhibitors: the replacement for warfarin, leeches, and pig intestines Angew. Chem., Int. Ed. 2011, 50, 4574-4590
4. Hauel, N. H.; Nar, H.; Priepke, H.; Ries, U.; Stassen, J. M.; Wienen, W. Structure-based design of novel potent nonpeptide thrombin inhibitors J. Med. Chem. 2002, 45, 1757-1766
5. Ieko, M. Drug evaluation: dabigatran etexilate, a thrombin inhibitor for the prevention of venous thromboembolism and stroke Curr. Opin. Invest. Drugs 2007, 8 (9) 758-768
6. Van Ryn, J.; Stangier, J.; Haertter, S.; Liesenfeld, K. H.; Wienen, W.; Feuring, M. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity Thromb. Haemostasis 2010, 103, 1116-1127
7. Hankey, G. J.; Eikelboom, J. W. Dabigatran etexilate: a new oral thrombin inhibitor Circulation 2011, 123, 1436-1450
8. Perzborn, E.; Roehring, S.; Straub, A.; Kubitza, D.; Misselwitz, F. The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor Nat. Rev. Drug Discovery 2011, 10, 61-75
9. Straub, A.; Roehrig, S.; Hillisch, A. Entering the era of non-basic P1 site groups: discovery of Xarelto (rivaroxaban) Curr. Top. Med. Chem. 2010, 10, 257-269
10. Misselwitz, F.; Berkowitz, S. D.; Perzborn, E. The discovery and development of rivaroxaban Ann. N.Y. Acad. Sci. 2011, 1222, 64-75
11. Furugohri, T.; Isobe, K.; Honda, Y.; Kamisato-Matsumoto, C.; Sugiyama, N.; Nagahara, T.; Morishima, Y.; Shibano, T. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles J. Thromb. Haemostasis 2008, 6, 1542-1549
12. Pinto, D. J. P.; Orwat, M. J.; Koch, S.; Rossi, K. A.; Alexander, R. S.; Smallwood, A.; Wong, P. C.; Rendina, A. R.; Luettgen, J. M.; Knabb, R. M.; He, K.; Xin, B.; Wexler, R. R.; Lam, P. Y. S. Discovery of 1-(4-methoxyphenyl)-7- oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1 H -pyrazolo[3,4- c ]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa J. Med. Chem. 2007, 50, 5339-5356
13. Wong, P. C.; Crain, X. B.; Xin, B.; Wexler, R. R.; Lam, P. Y. S.; Pinto, D. J.; Luettgen, J. M.; Knabb, R. M. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies J. Thromb. Haemostasis 2008, 6, 820-829
14. Herbert, J.-M.; Herault, J.-P.; Bernat, A.; Savi, P.; Schaeffer, P.; Driguez, P.-A.; Duchaussoy, P.; Petitou, M. SR123781A, a synthetic heparin mimetic Thromb. Haemostasis 2001, 85, 852-860
15. Petitou, M.; Duchaussoy, P.; Driguez, P.-A.; Jaurand, G.; Hérault, J.-P.; Lormeau, J.-C.; van Boeckel, C. A. A.; Herbert, J.-M. First synthetic carbohydrates with the full anticoagulant properties of heparin Angew. Chem., Int. Ed. 1998, 37 (21) 3009-3014
16. Petitou, M.; Hérault, J.-P.; Bernat, A.; Driguez, P.-A.; Duchaussoy, P.; Lormeau, J.-C.; Herbert, J.-M. Synthesis of thrombin-inhibiting heparin mimetics without side effects Nature 1999, 398, 417-422
17. Petitou, M.; Duchaussoy, P.; Driguez, P.-A.; Hérault, J.-P.; Lormeau, J.-C.; Herbert, J.-M. New synthetic heparin mimetics able to inhibit thrombin and factor Xa Bioorg. Med. Chem. Lett. 1999, 9 (8) 1155-1160
18. Li, W.; Johnson, D. J. D.; Esmon, C. T.; Huntington, J. A. Structure of the antithrombin-thrombin-heparin ternary complex reveals the antithrombotic mechanism of heparin Nat. Struct. Mol. Biol. 2004, 11, 857-862
19. De Kort, M.; Buijsmain, R. C.; Van Boeckel, A. A. Synthetic heparin derivatives as new anticoagulant drugs Drug Discovery Today 2005, 10, 769-779
20. Petitou, M.; Nancy-Porteboi, V.; Dubreucq, G.; Motte, V.; Meuleman, D.; De Kort, M.; Van Boeckel, C. A. A.; Vogel, G. M. T.; Wisse, J. A. J. The long way to a new pentasaccharide-based neutralisable anticoagulant with an unprecedented pharmacological profile Thromb. Haemostasis 2009, 102, 804-810
21. Nar, H.; Bauer, M.; Schmid, A.; Stassen, J. M.; Wienen, W.; Priepke, H. W.; Kauffmann, I. K.; Ries, U. J.; Hauel, N. H. Structural basis for inhibition promiscuity of dual specific thrombin and factor Xa blood coagulation inhibitors Structure 2001, 9, 29-37
22. Ries, U. J.; Priepke, H. W.; Hauel, N. H.; Handschuh, S.; Mihm, G.; Stassen, J. M.; Wienen, W.; Nar, H. Heterocyclic thrombin inhibitors. Part 2: Quinoxalinone derivatives as novel, potent antithrombotic agents Bioorg. Med. Chem. Lett. 2003, 13, 2297-2302
23. Graefe-Mody, E. U.; Schühly, U.; Rathgen, K.; Stähle, H.; Leitner, J. M.; Jilma, B. Pharmacokinetics and pharmacodynamics of BIBT 986, a novel small molecule dual inhibitor of thrombin and factor Xa J. Thromb. Haemostasis 2006, 4, 1502-1509
24. Deng, J. Z.; McMasters, D. R.; Rabbat, P. M.; Williams, P. D.; Coburn, C. A.; Yan, Y.; Kuo, L. C.; Lewis, S. D.; Lucas, B. J.; Krueger, J. A.; Strulovici, B.; Vacca, J. P.; Lyle, T. A.; Burgey, C. S. Development of an oxazolopyridine series of dual thrombin/factor Xa inhibitors via structure-guided lead optimization Bioorg. Med. Chem. Lett. 2005, 15, 4411-4416
25. Dönnecke, D.; Schweinitz, A.; Stürzebecher, A.; Steinmetzer, P.; Schuster, M.; Stürzebecher, U.; Nicklisch, S.; Stürzebecher, J.; Steinmetzer, T. From selective substrate analogue factor Xa inhibitors to dual inhibitors of thrombin and factor Xa. Part 3 Bioorg. Med. Chem. Lett. 2007, 17, 3322-3329
26. Young, R. J.; Brown, D.; Burns-Kurtis, C. L.; Chan, C.; Convery, M. A.; Hubbard, J. A.; Kelly, H. A.; Pateman, A. J.; Patikis, A.; Senger, S.; Shah, G. P.; Toomey, J. R.; Watson, N. S.; Zhou, P. Selective and dual action orally active inhibitors of thrombin and factor Xa Bioorg. Med. Chem. Lett. 2007, 17, 2927-2930
27. Maryanoff, B. E.; McComsey, D. F.; Costanzo, M. J.; Yabut, S. C.; Lu, T.; Player, M. R.; Giardino, E. C.; Damiano, B. P. Exploration of potential prodrugs of RWJ-445167, an oxyguanidine based dual inhibitor of thrombin and factor Xa Chem. Biol. Drug Des. 2006, 68, 29-36
28. Giardino, E. C.; Haertlein, B. J.; De Garavilla, L.; Costanzo, M. J.; Damiano, B. P.; Andrade-Gordon, P.; Maryanoff, B. E. Cooperative antithrombotic effect from the simultaneous inhibition of thrombin and factor Xa Blood Coagulation Fibrinolysis 2010, 21, 128-134
29. Altenburger, J.-M.; Lassalle, G. Y.; Matrougui, M.; Galtier, D.; Jetha, J.-C.; Bocskei, Z.; Berry, C. N.; Lunven, C.; Lorrain, J.; Herault, J.-P.; Schaeffer, P.; O'Connor, S. E.; Herbert, J.-M. SSR182289A, a selective and potent orally active thrombin inhibitor Bioorg. Med. Chem. 2004, 12, 1713-1730
30. Berry, C. N.; Lassalle, G.; Lunven, C.; Altenburger, J.-M.; Guilbert, F.; Lalé, A.; Hérault, J.-P.; Lecoffre, C.; Pfersdorff, C.; Herbert, J.-M.; O'Connor, S. E. SSR182289A, a novel, orally active thrombin inhibitor: in vitro profile and ex vivo anticoagulant activity J. Pharmacol. Exp. Ther. 2002, 303, 1189-1198
31. Lorrain, J.; Millet, L.; Lechaire, I.; Lochot, S.; Ferrari, P.; Visconte, C.; Sainte-Marie, M.; Lunven, C.; Berry, C. N.; Schaeffer, P.; Herbert, J.-M.; O'Connor, S. E. Antithrombotic properties of SSR182289A, a new, orally active thrombin inhibitor J. Pharmacol. Exp. Ther. 2002, 304, 567-574
32. Altenburger, J.-M.; Cremer, G.; Lassalle, G.; Matrougui, M. N -(Heterocyclyl)benzene or Pyridine Sulphonamides as Antithrombotic Agents and Anticoagulants. WO200170736 A1, 2001.
33. Maignan, S.; Guilloteau, J.-P.; Choi-Sledeski, Y. M.; Becker, M. R.; Ewing, W. R.; Pauls, H. W.; Spada, A. P.; Mikol, V. Molecular structures of human factor Xa complexed with ketopiperazine inhibitors: preference for a neutral group in the S1 pocket J. Med. Chem. 2003, 46, 685-690
34. Choi-Sledeski, Y. M.; Kearney, R.; Poli, G.; Pauls, H.; Gardner, C.; Gong, Y.; Becker, M.; Davis, R.; Spada, A.; Liang, G.; Chu, V.; Brown, K.; Collussi, D.; Leadley, R., Jr.; Rebello, S.; Moxey, P.; Morgan, S.; Bentley, R.; Kasiewski, C.; Maignan, S.; Guilloteau, J.-P.; Mikol, V. Discovery of an orally efficacious inhibitor of coagulation factor Xa which incorporates a neutral P1 ligand J. Med. Chem. 2003, 46, 681-684
35. Matter, H.; Nazaré, M.; Güssregen, S.; Will, D. W.; Schreuder, H.; Bauer, A.; Urmann, M.; Ritter, K.; Wagner, M.; Wehner, V. Evidence for C-Cl/C-Br···π Interactions as an Important Contribution to Protein-Ligand Binding Affinity Angew. Chem., Int. Ed. 2009, 48, 2911-2916
36. Roehrig, S.; Straub, A.; Pohlmann, J.; Lampe, T.; Pernerstorfer, S.; Schlemmer, K.-H.; Reinemer, P.; Perzborn, E. Discovery of the novel antithrombotic agent 5-chloro -N- ({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl) phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor J. Med. Chem. 2005, 48, 5900-5908
37. Knochel, P.; Dohle, W.; Gommermann, N.; Kneisel, F. F.; Kopp, F.; Korn, T.; Sapountzis, I.; Vu, V. A. Highly functionalized organomagnesium reagents prepared through halogen-metal exchange Angew. Chem., Int. Ed. 2003, 42, 4302-4320
38. Groth, U.; Schöllkopf, U. Asymmetric syntheses via heterocyclic intermediates; XVII1. Enantioselective synthesis of (R)-α-methyl- S -benzylcysteine methyl ester and (R)-α-methyl- S-t -butylcysteine methyl ester using l -valine as chiral auxiliary reagent Synthesis 1983, 1, 37-38
39. Gould, W. R.; McClanahan, T. B.; Welch, K. M.; Baxi, S. M.; Saiya-Cork, K.; Chi, L.; Johnson, T. R.; Leadley, R. J. Inhibitors of blood coagulation factors Xa and IIa synergize to reduce thrombus weight and thrombin generation in vivo and in vitro J. Thromb. Haemostasis 2006, 4, 834-841
40. Giardino, E. C.; Haertlein, B. J.; de Garavilla, L.; Costanzo, M. J.; Damiano, B. P.; Andrade-Gordon, P.; Maryanoff, B. E. Cooperative antithrombotic effect from the simultaneous inhibition of thrombin and factor Xa Blood Coagulation Fibrinolysis 2010, 21, 128-134
41. Follmann, M.; Wehner, V.; Meneyrol, J.; Altenburger, J.-M.; Petit, F.; Lassalle, G.; Herault, J. P. Preparation of Chlorothiophene-amides as Inhibitors of Coagulation Factors Xa and Thrombin. WO2009103440, 2009.
42. Follmann, M.; Wehner, V.; Altenburger, J.-M.; Lassalle, G.; Herault, J.-P.; Preparation of Chlorothiophene-isoxazoles as Inhibitors of Coagulation Factors Xa and Thrombin. WO2009103439, 2009.
43. Gutierrez, C. G.; Leo, R.; Summerhays, L. R. Organotin-mediated selective desulfurization: tri- n -butyltin hydride reduction of unsymmetric sulfides J. Org. Chem. 1984, 49 (26) 5206-5213
44. Nazaré, M.; Will, D. W.; Matter, H.; Schreuder, H.; Ritter, K.; Urmann, M.; Essrich, M.; Bauer, A.; Wagner, M.; Czech, J.; Lorenz, M.; Laux, V.; Wehner, V. Probing the subpockets of factor Xa reveals two binding modes for inhibitors based on a 2-carboxyindole scaffold: a study combining structure-activity relationship and X-ray crystallography J. Med. Chem. 2005, 48, 4511-4525
45. Nazaré, M.; Essrich, M.; Will, D. H.; Matter, H.; Ritter, K.; Urmann, M.; Bauer, A.; Schreuder, H.; Dudda, A.; Czech, J.; Lorenz, M.; Laux, V.; Wehner, V. Factor Xa inhibitors based on a 2-carboxyindole scaffold: SAR of neutral P1 substituents Bioorg. Med. Chem. Lett. 2004, 14, 4191-4195
46. Ham, J.; Yang, I.; Kang, H. A facile one-pot synthesis of alkyl aryl sulfides from aryl bromides J. Org. Chem. 2004, 69, 3236-3239
47. Cheng, Y.; Prusoff, W. H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction Biochem. Pharmacol. 1973, 22, 3099-3108
48. Segal, I. H. Enzyme Kinetics; John Wiley & Sons: New York, 1975; pp 100-125.
49. Hemker, H. C.; Beguin, S. Thrombin generation in plasma: its assessment via the endogenous thrombin potential Thromb. Haemostasis 1995, 74, 134-138
50. Nieuwenhuys, C. M.; Feijge, M. A.; Beguin, S.; Heemskerk, J. W. Monitoring hypocoagulant conditions in rat plasma: factors determining the endogenous thrombin potential of tissue factor-activated plasma Thromb. Haemostasis 2000, 84, 1045-1051
51. Matter, H.; Defossa, E.; Heinelt, U.; Blohm, P.-M.; Schneider, D.; Mueller, A.; Herok, S.; Schreuder, H.; Liesum, A.; Brachvogel, V.; Loenze, P.; Walser, A.; Al-Obeidi, F.; Wildgoose, P. Design and quantitative structure-activity relationship of 3-amidinobenzyl-1 H -indole-2-carboxamides as potent, nonchiral, and selective inhibitors of blood coagulation factor Xa J. Med. Chem. 2002, 45, 2749-2769
52. 2-alpha-thrombin crystallization and diffraction data J. Mol. Biol. 1989, 20 (206(4)) 755-757
53. Otwinowski, Z.; Minor, W. Processing of X-ray Diffraction Data Collected in Oscillation Mode. In Macromolecular Crystallography. Part A; Carter, C.W., Jr.; Sweet, R. M., Eds.; Methods in Enzymology, Vol. 276; Academic Press: New York, 1997; pp 307-326.
54. Emsley, P.; Cowtan, K. Coot: model-building tools for molecular graphics Acta Crystallogr. 2004, D60, 2126-2132
55. Bricogne, G.; Blanc, E.; Brandl, M.; Flensburg, C.; Keller, P.; Paciorek, W.; Roversi, P.; Sharff, A.; Smart, O. S.; Vonrhein, C.; Womack, T. O. BUSTER, version 2.11.2; Global Phasing Ltd.: Cambridge, U.K., 2011.
56. Kabsch, W. Evaluation of single-crystal X-ray diffraction data from a position sensitive detector J. Appl. Crystallogr. 1988, 21, 916-924
57. Collaborative Computational Project, Number 4. The CCP4 suite: programs for protein crystallography Acta Crystallogr. 1994, D50, 760-763
58. Brunger, A. T.; Adams, P. D.; Clore, G. M.; Gros, P.; Grosse-Kunstleve, R. W.; Jiang, J.-S.; Kuszewski, J.; Nilges, N.; Pannu, N. S.; Read, R. J.; Rice, L. M.; Simonson, T.; Warren, G. L. Crystallography & NMR System (CNS), a new software suite for macromolecular structure determination Acta Crystallogr. 1998, D54, 905-921
59. Schüttelkopf, A. W.; van Aalten, D. M. F. PRODRG-a tool for high-throughput crystallography of protein-ligand complexes Acta Crystallogr. 2004, D60, 1355-1363
60. Pannu, N. J.; Murshudov, G. N.; Dodson, E. J.; Read, R. J. Incorporation of prior phase information strengthen maximum-likelihood structure refinement Acta Crystallogr. 1998, D54, 1285-1294